The story of Viagra presents a intricate picture for shareholders. While the initial release generated massive gains, the lapse of its exclusive rights opened the avenue to generic competitors, dramatically diminishing revenue. This poses a particular dilemma for pharmaceutical companies relying on related blockbuster medications, suggesting that a

The legacy of Viagra, and its creator copyright, presents a complex case study for investors. At first a blockbuster drug, generating billions in revenue , its exclusivity period created a flood of knock-off medications, significantly diminishing its dominance. While some firms may attempt to capitalize on related treatments , the present landscape